French pharma giant Sanofi (NASDAQ:SNY) has agreed to sell global rights linked to Enjaymo, an FDA-approved treatment for an ...

Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US.

In October 2024, Recordati reached an agreement with Sanofi to acquire the worldwide rights to Enjaymo, the only approved ...

New advancements in Cold Agglutinin Disease treatments promise improved patient outcomes and market growth, driving innovation and investment in the sector.

Early detection of hepatocellular carcinoma (HCC) is crucial for improving survival in patients with chronic hepatitis.

A recent study highlights the potential benefits of oral semaglutide in managing type 2 diabetes mellitus (T2DM) for patients ...

AtLP are conditions in which it is not possible to differentiate between the benign and the malignant nature of a given lymphoid infiltrate. The descriptive term AtLP may be used as an interim ...

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

NAINR. 2004;4(4):231-239. Acanthocyte Erythrocyte identified by numerous spiny cytoplasmic projections; similar to a Burr cell Acanthocytosis, condition in which the majority of erythrocytes are ...